KALV - Kalvista Pharmaceuticals Inc

KALV - Kalvista Pharmaceuticals Inc

https://www.kalvista.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

KalVista Pharmaceuticals, Inc. ( KALV ) Reports Q1 Loss, Lags Revenue Estimates

Zacks Commentary • 4 days, 5 hours ago • score: 0.12

KalVista Pharmaceuticals (KALV) delivered earnings and revenue surprises of -23.08% and -20.91%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

KalVista Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call - KalVista Pharmaceuticals ( NASDAQ:KALV )

Benzinga • 5 days, 6 hours ago • score: 0.04

KalVista Pharmaceuticals, Inc. KALV will release earnings results for the first quarter before the opening bell on Thursday, Sept. 11. Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at 96 cents per share, versus a year-ago loss of 87 cents per share.

KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday - Amber International ( NASDAQ:AMBR ) , Baidu ( NASDAQ:BIDU )

Benzinga • 2 months, 1 week ago • score: 0.37

U.S. stocks were lower, with the Dow Jones index falling over 100 points on Monday. Shares of KalVista Pharmaceuticals, Inc. KALV rose sharply during Monday's session after the company announced it won FDA approval for EKTERLY. The U.S.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Range-Bound

As of 2025-09-10 (Snapshot)

KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops, and markets small-molecule protease inhibitors for illnesses with unmet needs. The company is headquartered in Cambridge, Massachusetts.

52W High

$16.32

52W Low

$7.30

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

-0.10

Valuation

As of 2025-04-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-3.53

EV/Revenue (<3 favorable)

76.33

P/S (TTM) (<3 favorable)

107.42

P/B (<3 favorable)

8.35

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.29%

Institutions (25–75% balanced)

109.80%

Shares Outstanding

50,340,000

Float

27,919,600

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-04-30 (Overview)

Revenue (TTM)

3,824,000

Gross Profit (TTM)

-71,709,000

EPS (TTM)

-3.69

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.22%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

0.31

Momentum

Bearish momentum

Value

0.5284

Previous

0.6680

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025